FY25 Performance - FY25 innovation launches generated over $300 million in retail sales[14] - FY25 innovation launches saw a 27% dollar growth compared to FY24 launches[15] - FY25 innovation launches experienced a 36% velocity improvement compared to FY24 launches[15] - Conagra's share of volume sales sold on promotion in Q2 FY25 reached 31%[20] - Conagra's domestic retail organic volume consumption grew by 0.7% in Q2 FY25[25] - 67% of Conagra's portfolio held or gained volume share in Q2 FY25[28] - Net debt reduced by $364 million year-over-year, reaching $8 billion in Q4 FY25[78] FY26 Outlook - FY26 organic net sales are projected to grow between -1% and +1%[83] - FY26 adjusted operating margin is expected to be approximately 110% to 115%[83] - FY26 adjusted EPS is forecasted to be in the range of $170 to $185[83] - Net M&A is expected to subtract approximately $540 million from reported net sales in FY26, while the 53rd week is projected to add approximately $200 million[87]

Core Viewpoint - Karolinska Development AB has divested its remaining shares in OssDsign, resulting in a capital injection of approximately SEK 34.5 million, which strengthens the company's liquidity and allows for prioritization of other investments with greater value creation potential [1][2]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying breakthrough medical innovations in the Nordic region, investing in the creation and growth of companies that advance these innovations into commercial products [4][5]. - The company has access to world-class medical innovations from the Karolinska Institutet and other leading universities and research institutes in the Nordic region, aiming to build companies around leading scientists supported by experienced management teams [5][6]. Investment Strategy - The divestment from OssDsign reflects a strategic decision to realize profits and enhance the financial position of Karolinska Development, enabling the company to invest in other holdings with higher potential returns [2][3]. - Following the divestment, Karolinska Development has no direct ownership in OssDsign but retains indirect ownership through the KCIF Co-Investment Fund [3]. Portfolio and Management - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for life-threatening or serious debilitating diseases, led by an entrepreneurial team of investment professionals with a proven track record [6].

Brady (BRC) Conference June 11, 2025 02:30 PM ET Speaker0 Good afternoon, everyone, and welcome back to Sidoti's Virtual Investor Conference. I do see there's still some people filling into the room. But I'll take this time right now and just remind everyone if you have questions, we expect a few minutes after the informative presentation. You press that q and a button at the bottom of your screen, type in the questions, and we'll get to as many as we can, time permitting. So happy to welcome CFO Anne Thorn ...

Shares of Eastman Kodak Company (KODK) have declined 7.1% since reporting results for the first quarter of 2025. This compares with the S&P 500 index’s 3.1% growth over the same time frame. Over the past month, the stock has lost 1.5% compared with the S&P 500’s 8.1% rally.Earnings & Revenue PerformancesKodak’s financial performance for the first quarter reflected stability in top-line revenues but pronounced weakness in profitability. The company reported consolidated revenues of $247 million, down 1% from ...

Rimini Street (RMNI) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Dean Pohl - VP of Investor Relations & TreasurerSeth Ravin - Founder, Chairman, CEO & PresidentMichael Perica - EVP, CFO & Principal Accounting OfficerBrian Kinstlinger - MD, Director of Research & Head of Technology ResearchCole Erskine - Vice President - Equity Research Operator Good afternoon, ladies and gentlemen, and welcome to the Rimini Street Q1 twenty twenty five Earnings Conference Call. At this time, all line ...

Financial Data and Key Metrics Changes - First quarter sales from continuing operations grew 5% on both a reported and operational basis, totaling $2.63 billion, exceeding previous guidance of 3% to 4% [8][13][34] - Adjusted earnings per share from continuing operations were $0.55, up 53% compared to the prior year, driven by favorable top line results and lower non-operational expenses [8][33] Business Line Data and Key Metrics Changes - Medical Products and Therapies (MPT) segment sales were $1.3 billion, increasing 6%, with strong growth in U.S. infusion systems [14][35] - Healthcare Systems and Technologies (HST) segment sales totaled $704 million, up 6%, driven by 14% growth in the U.S. for Care and Connectivity Solutions [19][20] - Pharmaceutical segment sales were $581 million, increasing 3%, with specialty injectables showing mid-single-digit growth [23] Market Data and Key Metrics Changes - The U.S. market showed strong recovery with hospitals beginning to rebuild inventory levels, particularly in IV Solutions, which is expected to improve as allocations are removed [17][22] - International sales performance was weaker, but capital orders picked up, indicating potential future growth [20] Company Strategy and Development Direction - The company is focused on leveraging its verticalized operating model to enhance innovation and drive profitable growth [6][8] - Strategic actions are being taken to mitigate the impact of global tariffs and optimize the supply chain [9][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic trajectory despite global macroeconomic volatility and uncertainty [9][10] - The company anticipates total sales growth of 7% to 8% for the full year 2025, with operational growth expected at 4% to 5% [34][42] Other Important Information - The search for a permanent CEO is active, with the board working with a leading search firm [10] - The company is committed to accelerating investments in innovation to redefine healthcare delivery [27] Q&A Session Summary Question: What actions are being taken to offset tariff headwinds? - Management is optimizing supply chains, negotiating with suppliers, and seeking exemptions while implementing targeted pricing strategies [46][50] Question: What is the outlook for the HST business recovery? - The HST segment showed strong performance with a healthy backlog and competitive wins, indicating positive momentum [52][54] Question: What impact do conservation programs have on IV Solutions? - Hospitals are expected to continue conservation efforts, but some are using more solutions than pre-hurricane levels, indicating a mixed recovery [60][62] Question: How is the company addressing potential pharmaceutical tariffs? - The company is proactively planning for potential tariff impacts and seeking exemptions, but the situation remains uncertain [66][68] Question: What is the outlook for operating margins in 2026? - The company remains committed to margin expansion, but the impact of tariffs and other factors will be evaluated as the situation develops [100]

STOCKHOLM, SWEDEN, April 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has notified a change of CEO during the second half of 2025. The purpose is to support the establishment of leadership with an even stronger presence and focus on the US market. OssDsign launched OssDsign Catalyst in the U.S. in August 2021. Since then, the company has undergone a strategic shift to become a pure-play orthobiologics company and has shown high double-digit growt ...

Core Points - The Annual General Meeting of Alfa Laval AB was held on April 29, 2025, where the Chairman and CEO presented the company's performance and strategic direction for the future [1][2] Financial Performance - The year 2024 was marked by record high invoicing and order intake, driven by strong demand for sustainable solutions across all divisions [2] - The income statement and balance sheet for 2024 were approved by the Annual General Meeting [3] Dividend Declaration - A dividend of SEK 8.50 per share was resolved, with a record date of May 2, 2025, and payment expected on May 7, 2025 [4] Board of Directors - The number of Board members was set to ten, with Dennis Jönsson re-appointed as Chairman [5][6] - Annica Bresky was elected as a new member of the Board, with all members elected for the term until the end of the 2026 Annual General Meeting [6] Auditors - The Annual General Meeting re-elected Andreas Troberg and Hanna Fehland as auditors, with Henrik Jonzén and Andreas Mast as deputy auditors for the upcoming year [7] Compensation - Compensation for the Board was set at SEK 2,190,000 for the Chairman and SEK 730,000 for other non-employee members, along with specific amounts for Audit and Remuneration Committee members [8]